Canada Markets open in 2 hrs 41 mins

I-Mab (IMAB)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
11.49+0.19 (+1.68%)
At close: 04:00PM EDT
11.49 0.00 (0.00%)
After hours: 04:00PM EDT
Sign in to post a message.
  • y
    y
    What is driving the selling today? The volume is twice normal range. It just released a positive news on one its trials.
  • f
    far
    Nice jump.. on way to $80
  • I
    Issa
    I dont understand why it went down that much !!
  • f
    far
    Institutional investors have been buying left and right over past few months as price has come down.. BUY
  • E
    Easy come EG
    A real takeover target 🎯…
  • M
    Mike
    today announced two assets the Company has licensed from partner MorphoSys AG (FSE: MOR; NASDAQ: MOR), felzartamab (also known as TJ202/MOR202) and TJ210 (also known as MOR210), are advancing globally through new license agreements.
  • E
    Easy come EG
    Why it is so much down???
  • y
    y
    Here is Morningstar's view on the reasons IMAB stock sank last Fri: "The most negative things we can glean from the disclosure are the lack of clear signals of superiority over Astra’s data, the lower response in PD-1 refractory patients and second line settings, and the small pool of evaluable patients (n=15) indicating slow progress." It sounds reasonable, but the stock is still highly risky even to Morningstar. Most clinical stage companies don't get out of the clinical stage. And being a China based company subjected to delisting, failure of CD47 or CD73 could be fatal. In current environment, I will wait--worth a bet but not yet.
  • Y
    Yahoo Finance Insights
    IMAB reached a 52 Week low at 11.51
  • b
    bloodyman
    (KOD) trading 50% UNDER cash + 4x BIG PHASE 3 near readouts for FREE = $$$$$$$$$$$$$$
  • M
    MJ34
    Two phase 3 Trials in China, two phase 2 trials in China, and seven phase 1 trials in the US and China. Holding this one long.
  • Y
    Yahoo Finance Insights
    IMAB reached a 52 Week low at 11.87
  • y
    y
    I wonder who are the interested acquirers. ABBV secured the North America's right for imab's most important clinical drug. Any buyer other ABBV must pay to break-up that deal, assuming ABBV will accept the deal. But ABBV's acceptance would raise a red flag on that drug's prospect. No company would give a promising drug for a 'bargain' price that ABBV struck.
  • A
    Anonymous
    This forum is pretty quiet. I bought imab more than a year ago and very happy to see the growth of this stock.
  • E
    Eddy
    Buy and hold!
  • F
    Florian
    Building up momentum. Without being really noticed from a broader audience so far. Enjoy the ride & GLTAL
  • S
    Sandra
    Do these folks have an AD cure in a nasal spray?
  • F
    Frankenstein
    Ok, this company got into the US Stock market around when the US first got a case of CV-19. I’m not saying but I’m saying. It’s a buy
  • b
    besanceney
    (http://Rightpicker.com) is a must for any trader. Their watchlist which covers pre-market movers is one of the best researched in the industry. I don’t start trading without reading their daily email each morning!
  • J
    Jason Gustavo Esperado
    Mehhhh $AFMD got a $5B deal with Roche.